168 related articles for article (PubMed ID: 10318765)
1. Activation-dependent clustering of the erbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy.
Nagy P; Jenei A; Kirsch AK; Szöllosi J; Damjanovich S; Jovin TM
J Cell Sci; 1999 Jun; 112 ( Pt 11)():1733-41. PubMed ID: 10318765
[TBL] [Abstract][Full Text] [Related]
2. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
3. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
4. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging.
Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ
J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028
[TBL] [Abstract][Full Text] [Related]
5. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
7. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
9. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2.
Nagy P; Vereb G; Sebestyén Z; Horváth G; Lockett SJ; Damjanovich S; Park JW; Jovin TM; Szöllosi J
J Cell Sci; 2002 Nov; 115(Pt 22):4251-62. PubMed ID: 12376557
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
11. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
Barbacci EG; Pustilnik LR; Rossi AM; Emerson E; Miller PE; Boscoe BP; Cox ED; Iwata KK; Jani JP; Provoncha K; Kath JC; Liu Z; Moyer JD
Cancer Res; 2003 Aug; 63(15):4450-9. PubMed ID: 12907618
[TBL] [Abstract][Full Text] [Related]
12. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
[TBL] [Abstract][Full Text] [Related]
13. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
Esparís-Ogando A; Díaz-Rodríguez E; Montero JC; Yuste L; Crespo P; Pandiella A
Mol Cell Biol; 2002 Jan; 22(1):270-85. PubMed ID: 11739740
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
15. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Mapping ErbB receptors on breast cancer cell membranes during signal transduction.
Yang S; Raymond-Stintz MA; Ying W; Zhang J; Lidke DS; Steinberg SL; Williams L; Oliver JM; Wilson BS
J Cell Sci; 2007 Aug; 120(Pt 16):2763-73. PubMed ID: 17652160
[TBL] [Abstract][Full Text] [Related]
18. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T; Wang Y; Zhao ZJ; Gu H
J Biol Chem; 2010 May; 285(20):14861-14870. PubMed ID: 20335174
[TBL] [Abstract][Full Text] [Related]
19. ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells.
Keely SJ; Barrett KE
J Biol Chem; 1999 Nov; 274(47):33449-54. PubMed ID: 10559227
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
Xia W; Mullin RJ; Keith BR; Liu LH; Ma H; Rusnak DW; Owens G; Alligood KJ; Spector NL
Oncogene; 2002 Sep; 21(41):6255-63. PubMed ID: 12214266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
